Therapeutic targeting of the tumor microenvironment

L Bejarano, MJC Jordāo, JA Joyce - Cancer discovery, 2021 - AACR
Strategies to therapeutically target the tumor microenvironment (TME) have emerged as a
promising approach for cancer treatment in recent years due to the critical roles of the TME …

Tumor-associated macrophages: an accomplice in solid tumor progression

Y Chen, Y Song, W Du, L Gong, H Chang… - Journal of biomedical …, 2019 - Springer
In many solid tumor types, tumor-associated macrophages (TAMs) are important
components of the tumor microenvironment (TME). Moreover, TAMs infiltration is strongly …

Targeting macrophages: therapeutic approaches in cancer

L Cassetta, JW Pollard - Nature reviews Drug discovery, 2018 - nature.com
Infiltration of macrophages in solid tumours is associated with poor prognosis and correlates
with chemotherapy resistance in most cancers. In mouse models of cancer, macrophages …

Progress in tumor-associated macrophage (TAM)-targeted therapeutics

C Ngambenjawong, HH Gustafson, SH Pun - Advanced drug delivery …, 2017 - Elsevier
As an essential innate immune population for maintaining body homeostasis and warding
off foreign pathogens, macrophages display high plasticity and perform diverse supportive …

Interaction of tumor-associated macrophages and cancer chemotherapy

I Larionova, N Cherdyntseva, T Liu, M Patysheva… - …, 2019 - Taylor & Francis
It has been recently recognized that the tumor microenvironment (TME) is an essential factor
that defines the efficiency of chemotherapy. The local TME, consisting of immune cells with …

Pan-cancer analysis of immune cell infiltration identifies a prognostic immune-cell characteristic score (ICCS) in lung adenocarcinoma

S Zuo, M Wei, S Wang, J Dong, J Wei - Frontiers in immunology, 2020 - frontiersin.org
Background: The tumor microenvironment (TME) consists of heterogeneous cell
populations, including malignant cells and nonmalignant cells that support tumor …

[HTML][HTML] Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death

Y Moon, MK Shim, J Choi, S Yang, J Kim, WS Yun… - Theranostics, 2022 - ncbi.nlm.nih.gov
Rationale: Cancer immunotherapy combining immune checkpoint blockade (ICB) with
chemotherapeutic drugs has provided significant clinical advances. However, such …

[HTML][HTML] The role of tumor-stroma interactions in drug resistance within tumor microenvironment

Y Ni, X Zhou, J Yang, H Shi, H Li, X Zhao… - Frontiers in Cell and …, 2021 - frontiersin.org
Cancer cells resistance to various therapies remains to be a key challenge nowadays. For a
long time, scientists focused on tumor cells themselves for the mechanisms of acquired drug …

[HTML][HTML] The twin cytokines interleukin-34 and CSF-1: masterful conductors of macrophage homeostasis

J Muñoz-Garcia, D Cochonneau, S Télétchéa… - Theranostics, 2021 - ncbi.nlm.nih.gov
Macrophages are specialized cells that control tissue homeostasis. They include non-
resident and tissue-resident macrophage populations which are characterized by the …

Delivery of an ectonucleotidase inhibitor with ROS-responsive nanoparticles overcomes adenosine-mediated cancer immunosuppression

C Mao, S Yeh, J Fu, M Porosnicu, A Thomas… - Science translational …, 2022 - science.org
Tumor evasion of immune destruction is associated with the production of
immunosuppressive adenosine in the tumor microenvironment (TME). Anticancer therapies …